QQQ   416.27 (-1.69%)
AAPL   164.62 (-1.45%)
MSFT   398.90 (-1.33%)
META   481.97 (-3.95%)
GOOGL   153.12 (-1.85%)
AMZN   174.66 (-2.54%)
TSLA   148.65 (-0.85%)
NVDA   810.00 (-4.34%)
AMD   148.61 (-4.17%)
NIO   3.82 (-4.50%)
BABA   68.57 (-0.45%)
T   16.33 (+0.00%)
F   12.08 (+0.17%)
MU   106.92 (-4.48%)
GE   148.19 (-3.11%)
CGC   8.02 (+2.43%)
DIS   111.78 (-0.58%)
AMC   3.26 (+11.64%)
PFE   25.77 (+1.50%)
PYPL   61.98 (-0.19%)
XOM   119.94 (+1.20%)
QQQ   416.27 (-1.69%)
AAPL   164.62 (-1.45%)
MSFT   398.90 (-1.33%)
META   481.97 (-3.95%)
GOOGL   153.12 (-1.85%)
AMZN   174.66 (-2.54%)
TSLA   148.65 (-0.85%)
NVDA   810.00 (-4.34%)
AMD   148.61 (-4.17%)
NIO   3.82 (-4.50%)
BABA   68.57 (-0.45%)
T   16.33 (+0.00%)
F   12.08 (+0.17%)
MU   106.92 (-4.48%)
GE   148.19 (-3.11%)
CGC   8.02 (+2.43%)
DIS   111.78 (-0.58%)
AMC   3.26 (+11.64%)
PFE   25.77 (+1.50%)
PYPL   61.98 (-0.19%)
XOM   119.94 (+1.20%)
QQQ   416.27 (-1.69%)
AAPL   164.62 (-1.45%)
MSFT   398.90 (-1.33%)
META   481.97 (-3.95%)
GOOGL   153.12 (-1.85%)
AMZN   174.66 (-2.54%)
TSLA   148.65 (-0.85%)
NVDA   810.00 (-4.34%)
AMD   148.61 (-4.17%)
NIO   3.82 (-4.50%)
BABA   68.57 (-0.45%)
T   16.33 (+0.00%)
F   12.08 (+0.17%)
MU   106.92 (-4.48%)
GE   148.19 (-3.11%)
CGC   8.02 (+2.43%)
DIS   111.78 (-0.58%)
AMC   3.26 (+11.64%)
PFE   25.77 (+1.50%)
PYPL   61.98 (-0.19%)
XOM   119.94 (+1.20%)
QQQ   416.27 (-1.69%)
AAPL   164.62 (-1.45%)
MSFT   398.90 (-1.33%)
META   481.97 (-3.95%)
GOOGL   153.12 (-1.85%)
AMZN   174.66 (-2.54%)
TSLA   148.65 (-0.85%)
NVDA   810.00 (-4.34%)
AMD   148.61 (-4.17%)
NIO   3.82 (-4.50%)
BABA   68.57 (-0.45%)
T   16.33 (+0.00%)
F   12.08 (+0.17%)
MU   106.92 (-4.48%)
GE   148.19 (-3.11%)
CGC   8.02 (+2.43%)
DIS   111.78 (-0.58%)
AMC   3.26 (+11.64%)
PFE   25.77 (+1.50%)
PYPL   61.98 (-0.19%)
XOM   119.94 (+1.20%)
Free Trial
LON:AGY

Allergy Therapeutics (AGY) Share Price, News & Analysis

→ The “Perfect Storm” for Gold (From Gold Safe Exchange) (Ad)
Free AGY Stock Alerts
GBX 2.70
-0.15 (-5.26%)
(As of 04:35 PM ET)
Compare
Today's Range
2.65
▼
2.70
50-Day Range
2.40
▼
3
52-Week Range
0.80
▼
3.90
Volume
1.43 million shs
Average Volume
797,267 shs
Market Capitalization
£128.79 million
P/E Ratio
N/A
Dividend Yield
8.33%
Price Target
N/A
Stock AnalysisChartCompetitorsHeadlines
AGY stock logo

About Allergy Therapeutics Stock (LON:AGY)

Allergy Therapeutics plc, a commercial biotechnology company, engages in the research and development of allergy treatments. The company sells injectable and sublingual allergen-specific immunotherapies; and offers prescription for the treatment of pollen-related allergies particularly to grasses, weeds, and trees, as well as diagnostics. Its products include Pollinex Quattro, Oralvac, Venomil, Venom ATL Polistes Dominula, Acarovac Plus, Pollinex, Synbiotics, and VLP Peanut. The company develops allergy vaccines for pollen, house dust mites, and animal fur, as well as peanut allergy vaccines. It operates in Central Europe, Southern Europe, the United Kingdom, and internationally. Allergy Therapeutics plc was incorporated in 2004 and is headquartered in Worthing, the United Kingdom.

AGY Stock Price History

AGY Stock News Headlines

April 18, 2024 | dailymail.co.uk
The most common 'inhalant' allergies
March 29, 2024 | finance.yahoo.com
Allergy Therapeutics First Half 2024 Earnings: UK£0.006 loss per share (vs UK£0.013 loss in 1H 2023)
April 19, 2024 | Gold Safe Exchange (Ad)
The “Perfect Storm” for Gold
Gold has already reached all-time highs, and experts believe it's not slowing down any time soon. In fact, some analysts predict a $7,000 price tag by 2025.
March 28, 2024 | lse.co.uk
AIM WINNERS & LOSERS: Norman Broadbent profit swing on rising revenue
March 2, 2024 | finance.yahoo.com
Allergy Therapeutics plc (AGY.L)
November 8, 2023 | morningstar.com
Allergy Therapeutics PLC AGY
November 6, 2023 | marketwatch.com
Allergy Therapeutics Extends Cash Runway to End of Year
October 14, 2023 | finance.yahoo.com
Allergy Therapeutics (LON:AGY) dips 10.0% this week as increasing losses might not be inspiring confidence among its investors
April 19, 2024 | Gold Safe Exchange (Ad)
The “Perfect Storm” for Gold
Gold has already reached all-time highs, and experts believe it's not slowing down any time soon. In fact, some analysts predict a $7,000 price tag by 2025.
October 13, 2023 | marketwatch.com
Allergy Therapeutics to Raise GBP40.75 Mln; Mandatory Cash Offer Triggered
July 31, 2023 | abcnews.go.com
Red meat allergy caused by ticks is an 'emerging public health concern': CDC
June 22, 2023 | forbes.com
What Is A Mold Allergy? Symptoms, Causes And Treatments
June 19, 2023 | marketwatch.com
Allergy Therapeutics Shares Fall on Going Concern Uncertainty
June 14, 2023 | technews.tmcnet.com
Generational Equity Advises Allergy, Sinus & Asthma Family Health Center in its Sale to AllerVie Health
June 12, 2023 | msn.com
Intellia Therapeutics stock gains on CRISPR treatment results
June 12, 2023 | msn.com
Why Intellia Therapeutics Stock Is Rising Monday
June 9, 2023 | proactiveinvestors.com
Allergy Therapeutics to present key scientific findings from its research portfolio
May 26, 2023 | benzinga.com
Global Allergy Immunotherapies Market Report 2023: Growing Consumer Awareness Towards Health Benefits of Allergy Immunotherapies Fuels the Sector
May 9, 2023 | marketwatch.com
Global Food Allergy Diagnostics And Therapeutics Market Increasing Demand with Leading Player, Comprehensive Analysis, Forecast 2030
May 5, 2023 | marketwatch.com
Peanut Allergy Therapeutics Market Projected to Reach Significant Growth Value by 2030
April 19, 2023 | proactiveinvestors.com
Allergy Therapeutics peanut vaccine candidate negotiates its early clinical hurdle
April 11, 2023 | finance.yahoo.com
Form 8.3 - The Allergy Therapeutics Plc
April 7, 2023 | forbes.com
Nasal Spray For Allergies: What You Need To Know
March 29, 2023 | usatoday.com
Spring is here—here’s what you need to survive seasonal allergies
March 29, 2023 | marketwatch.com
Global Mugwort Pollen and Allergies Therapeutics Drug Market : Latest Report 2029
March 28, 2023 | marketwatch.com
2023 Allergy Treatment Market: Best Practices of Top Players and Business Success Plans till 2030
March 28, 2023 | marketwatch.com
Allergy Diagnostics And Therapeutics Market by 2031
See More Headlines
Receive AGY Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Allergy Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
3/04/2020
Today
4/19/2024
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
LON
Sector
Medical
Industry
Drug Manufacturers - Specialty & Generic
Sub-Industry
N/A
Current Symbol
LON:AGY
CUSIP
N/A
CIK
N/A
Web
www.allergytherapeutics.com
Phone
+44-1903-844700
Fax
N/A
Employees
612
Year Founded
N/A

Profitability

EPS (Most Recent Fiscal Year)
GBX (0.06)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
-30.7
Net Income
£-43,070,000.00
Net Margins
-72.28%
Pretax Margin
N/A
Return on Equity
-216.27%
Return on Assets
-31.48%

Debt

Debt-to-Equity Ratio
1,741.96
Current Ratio
1.81
Quick Ratio
1.48

Sales & Book Value

Annual Sales
£59.59 million
Price / Sales
2.16
Cash Flow
GBX 0.74 per share
Price / Cash Flow
3.66
Book Value
N/A
Price / Book
N/A

Miscellaneous

Outstanding Shares
4,770,000,000
Free Float
N/A
Market Cap
£128.79 million
Optionable
Not Optionable
Beta
1.31
(Almost) Everything You Need To Know About The EV Market Cover
(Almost) Everything You Need To Know About The EV Market

Click the link below and we'll send you MarketBeat's guide to investing in electric vehicle technologies (EV) and which EV stocks show the most promise.

Get This Free Report

Key Executives

  • Mr. Manuel Llobet (Age 59)
    CEO & Executive Director
    Comp: $411.98k
  • Mr. Shaun Antony Furlong (Age 48)
    CFO & Executive Director
  • Ms. Beverly Lees
    Group Operations Director
  • Simon Piggott
    Head of Clinical Science
  • Alan Bullimore
    Head of Communication & Market Development
  • Karley Charlotte Mouatt Cheesman
    Company Secretary
  • Mr. Matthew Heath
    Principal Scientist

Key Competitors

View All Competitors

Insiders


AGY Stock Analysis - Frequently Asked Questions

How have AGY shares performed in 2024?

Allergy Therapeutics' stock was trading at GBX 2.50 at the start of the year. Since then, AGY shares have increased by 8.0% and is now trading at GBX 2.70.
View the best growth stocks for 2024 here.

How were Allergy Therapeutics' earnings last quarter?

Allergy Therapeutics plc (LON:AGY) issued its quarterly earnings data on Wednesday, March, 4th. The company reported $2.40 earnings per share for the quarter. Allergy Therapeutics had a negative net margin of 72.28% and a negative trailing twelve-month return on equity of 216.27%.

What other stocks do shareholders of Allergy Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Allergy Therapeutics investors own include (RLYP) (RLYP), Royalty Pharma (RPRX), Verastem (VSTM), Berkeley Energia (BKY), Burford Capital (BUR), Direxion Daily Gold Miners Index Bear 2x Shares (DUST), Flowtech Fluidpower (FLO), Merrimack Pharmaceuticals (MACK) and Shanta Gold (SHG).

How do I buy shares of Allergy Therapeutics?

Shares of AGY stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.
Compare Top Brokerages Here.

This page (LON:AGY) was last updated on 4/19/2024 by MarketBeat.com Staff

From Our Partners
Biden’s $374B Giveaway Into This Sector
DTI
The #1 Crypto for 2024
InvestorPlace
He Is Giving Away Bitcoin
Crypto Swap Profits
Urgent alert: open this for a huge profit potential
Timothy Sykes
How Biden has already won 2024
Porter & Company
Top 5 AI Stocks to Buy for 2024
Market Moving Trends
My biggest AI fear
Paradigm Press
Options trading has suddenly become more reliable.
Eagle Publishing